Vaccine Manufacturers – News and current trends

In the wake of the COVID19 pandemic and the evolution of mRNA vaccines, the global vaccine industry in 2025 is characterized by rapid expansion of manufacturing capacity, especially for mRNA and other novel platforms (“quick-high volume-cheap- simple”), alongside a strategic push to regionalize production and reduce dependence on a small number of suppliers. (WHO) Western world (North America, Europe) In North America and Europe, manufacturers are pivoting from pandemic COVID-19 revenues to a broader portfolio of respiratory, oncology, and maternal vaccines, with mRNA remaining a central technology platform. Moderna’s new innovation and manufacturing center in Oxfordshire and multiple US and EU facility expansions are geared to multi-product mRNA capacity for influenza, RSV, and future pandemic threats, while regulators in the US and EU continue to refine guidance on variant updated COVID-19 vaccines and combined respiratory products. Investment reports highlight that much of recent partnership activity involves co-development and fill-finish agreements, aiming...